Jan. 16, 2019 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG)
(“EyeGate” or “the Company”) today confirmed that it is scheduled to meet with
the U.S. Food and Drug Administration (FDA) on Wednesday, March 20th,
2019 to discuss EyeGate’s de novo application strategy for its Ocular Bandage
Gel (OBG) product, which will cover the clinical plan, data to date, and potential submission timelines. EyeGate’s
OBG platform, a unique cross-linked hyaluronic acid compound, has potentially
broad applications in managing ocular surface damage due to a variety of
conditions, ranging from punctate epitheliopathies (PE) commonly found in dry
eye patients, to large epithelial defects like those that occur following
photorefractive keratectomy (PRK).
EyeGate is a clinical-stage specialty pharmaceutical company focused on
developing and commercializing products using its two proprietary platform
technologies for treating diseases and disorders of the eye.
platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid
(CMHA-S), a modified form of the natural polymer hyaluronic acid, which is a
gel that possesses unique physical and chemical properties such as hydrating
and healing when applied to the ocular surface. The ability of CMHA-S to adhere
longer to the ocular surface, resist degradation and protect the ocular surface
makes it well-suited for treating various ocular surface injuries including surgical
EyeGate’s other product in clinical trials, incorporates a reformulated
topically active corticosteroid, Dexamethasone Phosphate that is delivered into
the ocular tissues through EyeGate’s proprietary innovative drug delivery system,
the EyeGate II Delivery System. For more information, please visit
EyeGate Social Media
EyeGate uses its website (www.EyeGatePharma.com), Facebook page (https://www.facebook.com/ EyeGatePharma/), corporate Twitter account (https://twitter.com/EyeGatePharma), and LinkedIn page (https://www.linkedin.com/company/135892/) as channels of distribution of information about EyeGate and its product candidates. Such information may be deemed material information, and EyeGate may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor EyeGate’s website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts. The social media channels that EyeGate intends to use as a means of disclosing the information described above may be updated from time to time as listed on EyeGate’s investor relations website.
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include statements relating to, among other things, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGate’s products, including EyeGate’s OBG product, its EGP-437 Combination Product, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, certain risk factors described under the heading “Risk Factors” contained in EyeGate’s Annual Report on Form 10-K filed with the SEC on March 2, 2018 or described in EyeGate’s other public filings. EyeGate’s results may also be affected by factors of which EyeGate is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. EyeGate expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.
Joseph Green / Wiktoria O’Hare
Edison Advisors for EyeGate Pharmaceuticals
646-653-7030 / 7028
email@example.com / firstname.lastname@example.org